Coherus Oncology (CHRS) Net Income towards Common Stockholders (2013 - 2026)
Coherus Oncology (CHRS) reported Net Income towards Common Stockholders of -$20.63 million for Q2 2026, compared with $297.77 million a year earlier.
Powered by 
Analysis
Coherus Oncology (CHRS) Net Income towards Common Stockholders (2013 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Coherus Oncology's Net Income towards Common Stockholders came in at -$132.13 million; for FY2025, it was $168.02 million, up 489.4% from FY2024.
- Net Income towards Common Stockholders has a five-year compound annual growth rate of 4.9% (FY2020 to FY2025).
- By year, Net Income towards Common Stockholders came in at $28.51 million in FY2024, -$237.89 million in FY2023, -$291.75 million in FY2022 and -$287.1 million in FY2021.
- Five-year quarterly Net Income towards Common Stockholders spans a low of -$96.08 million in Q1 2022 and a high of $297.77 million in Q2 2025.
- Per Business Quant data, the three quarters before Q2 2026 came in at -$38.33 million (Q1 2026), -$37.64 million (Q4 2025) and -$35.53 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,224.11 Bn | 1,197.72 Bn | 20.46 Bn | 6.45 Bn |
| 2 | Johnson & Johnson | 665.34 Bn | 585.20 Bn | 17.30 Bn | 210.00 Mn |
| 3 | AbbVie | 515.72 Bn | 483.73 Bn | 13.12 Bn | 4.22 Bn |
| 4 | Merck | 362.64 Bn | 325.58 Bn | 13.19 Bn | 5.07 Bn |
| 5 | Novartis Ag | 315.51 Bn | 288.75 Bn | - | - |
| 6 | Astrazeneca | 289.26 Bn | 263.15 Bn | 13.26 Bn | 3.12 Bn |
| 7 | Amgen | 249.20 Bn | 200.85 Bn | 7.58 Bn | 3.86 Bn |
| 8 | Gilead Sciences | 207.48 Bn | 182.59 Bn | 6.73 Bn | 2.43 Bn |
| 9 | Pfizer | 167.49 Bn | 114.85 Bn | 12.56 Bn | 3.24 Bn |
| 10 | Coherus Oncology | 119.30 Mn | -516.84 Mn | 10.07 Mn | -20.63 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -20.63 Mn |
| Mar 31, 2026 | -38.33 Mn |
| Dec 31, 2025 | -37.64 Mn |
| Sep 30, 2025 | -35.53 Mn |
| Jun 30, 2025 | 297.77 Mn |
| Mar 31, 2025 | -56.57 Mn |
| Dec 31, 2024 | -50.70 Mn |
| Sep 30, 2024 | -10.75 Mn |
| Jun 30, 2024 | -12.92 Mn |
| Mar 31, 2024 | 102.88 Mn |
| Dec 31, 2023 | -79.65 Mn |
| Sep 30, 2023 | -39.64 Mn |
| Jun 30, 2023 | -42.87 Mn |
| Mar 31, 2023 | -75.73 Mn |
| Dec 31, 2022 | -58.87 Mn |
| Sep 30, 2022 | -86.65 Mn |
| Jun 30, 2022 | -50.15 Mn |
| Mar 31, 2022 | -96.08 Mn |
| Dec 31, 2021 | -45.73 Mn |
| Sep 30, 2021 | -38.53 Mn |
API Access
Coherus Oncology Net Income towards Common Stockholders API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=CHRS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-income-towards-common-stockholders", "ticker": "CHRS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=CHRS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();